RESEARCH ARTICLE

The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de novo constitutive DNMT3A variants [version 1; peer review: 3 approved]


Clinical Assessment of the Utility of Sequencing and Evaluation as a Service (CAUSES) Research Study,

Abstract

Tatton-Brown-Rahman syndrome (TBRS; OMIM 615879), also known as the DNMT3A-overgrowth syndrome, is an overgrowth intellectual disability syndrome first described in 2014 with a report of 13 individuals with constitutive heterozygous DNMT3A variants. Here we have undertaken a detailed clinical study of 55 individuals with de novo DNMT3A variants, including the 13 previously reported individuals. An intellectual disability and overgrowth were reported in >80% of individuals with TBRS and were designated major clinical associations. Additional frequent clinical associations (reported in 20-80% individuals) included an evolving facial appearance with low-set, heavy, horizontal eyebrows and prominent upper central incisors; joint hypermobility (74%); obesity (weight >2SD, 67%); hypotonia (54%); behavioural/psychiatric issues (most frequently autistic spectrum disorder, 51%); kyphoscoliosis (33%) and afebrile seizures (22%). One individual was diagnosed with acute myeloid leukaemia in teenage years. Based upon the results from this study, we present our current management for individuals with TBRS.
Keywords
DNMT3A, Tatton-Brown-Rahman, overgrowth, intellectual disability

This article is included in the Transforming Genetic Medicine Initiative (TGMI) gateway.

Corresponding author: Katrina Tatton-Brown (ktatton@sgul.ac.uk)

Author roles: Tatton-Brown K: Conceptualization, Investigation, Methodology, Supervision, Writing – Original Draft Preparation; Zachariou A: Data Curation, Project Administration; Loveday C: Investigation; Renwick A: Investigation; Mahamadallie S: Investigation; Aksglaede L: Resources; Baralle D: Resources; Barge-Schaapveld D: Resources; Blyth M: Resources; Bouma M: Resources; Breckpot J: Resources; Crabb B: Resources; Dabir T: Resources; Cormier-Daire V: Resources; Fauth C: Resources; Fisher R: Resources; Gener B: Resources; Goudie D: Resources; Homfray T: Resources; Hunter M: Resources; Jorgensen A: Resources; Kant SG: Resources; Kirally-Borri C: Resources; Kooien D: Resources; Kumar A: Resources; Labilloy A: Resources; Lees M: Resources; Marcelis C: Resources; Mercer C: Resources; Mignot C: Resources; Miller K: Resources; Neas K: Resources; Newbury-Ecob R: Resources; Pilz DT: Resources; Posmyk R: Resources; Prada C: Resources; Ramsey K: Resources; Randolph LM: Resources; Selicorni A: Resources; Shears D: Resources; Suri M: Resources; Temple IK: Resources; Turnpenny P: Resources; Val Maldergem L: Resources; Varghese V: Resources; Veenstra-Knol HE: Resources; Yachelevich N: Resources; Yates L: Resources; Rahman N: Conceptualization, Funding Acquisition, Methodology, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: K.T.-B. is supported by funding from the Child Growth Foundation (GR01/13) and the Childhood Overgrowth Study is funded by the Wellcome Trust [100210]. The CAUSES Study is funded by Mining for Miracles, British Columbia Children’s Hospital Foundation and Genome British Columbia. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute [098051]. The DDD study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. This study makes use of DECIPHER (http://decipher.sanger.ac.uk), which is funded by the Wellcome Trust.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Tatton-Brown K et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Tatton-Brown K, Zachariou A, Loveday C et al. The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de novo constitutive DNMT3A variants [version 1; peer review: 3 approved] Wellcome Open Research 2018, 3:46 (https://doi.org/10.12688/wellcomeopenres.14430.1)

First published: 23 Apr 2018, 3:46 (https://doi.org/10.12688/wellcomeopenres.14430.1)
Introduction

Tatton-Brown-Rahman syndrome (TBRS; OMIM 615879), also known as the DNMT3A-overgrowth syndrome, is an overgrowth intellectual disability (OGID) syndrome first described in 2014 with a report of 13 individuals with de novo heterozygous DNMT3A variants\(^1,2\). Subsequently, a further 22 individuals with TBRS have been reported\(^3-9\).

In this report we have undertaken a detailed clinical evaluation of 55 individuals with de novo DNMT3A variants, including the 13 individuals we first reported in 2014. We have expanded and clarified the TBRS phenotype, delineating major and frequent clinical associations, which has informed our management of individuals with this new OGID syndrome.

Methods

The study was approved by the London Multicentre Research Ethics Committee (MREC MREC/01/2/44). Patients were identified through Clinical Genetics Services worldwide and written informed consent was obtained from all participating individuals and/or parents. Photographs, with accompanying written informed consent to publish, were requested from all participants and received from the families of 41 individuals. Detailed phenotype data were collected through a standardized clinical proforma, a DNMT3A specific clinical proforma and clinical review by one of the authors. Growth parameter standard deviations were calculated with reference to UK90 growth data\(^10\).

The degree of intellectual disability was defined in relation to educational support as a child and living impairment as an adult:

- an individual with a mild intellectual disability typically had delayed milestones but would attend a mainstream school with some support and live independently, with support, as an adult;
- an individual with a moderate intellectual disability typically required high level support in a mainstream school or special educational needs schooling and would live with support as an adult;
- an individual with a severe intellectual disability typically required special educational needs schooling, had limited speech, and would not live independently as an adult.

55 individuals were included with a range of de novo heterozygous DNMT3A variants: missense variants (36 individuals with 30 different variants); stop gain variants (six individuals); frameshift variants (six individuals); whole gene deletions (four individuals including identical twins (COG1961 and COG2006)); in-frame deletions (two individuals) and a splice site variant (one individual, Figure 1, Table 1). Computational tools predicted all 30 missense variants to be deleterious (Mutation Taster2 and SIFT (version 6.2.1), Supplementary Table 1) and the splice site variant was predicted to disrupt normal splicing. Importantly, some of the variants are common in the general population due to

![Figure 1. DNMT3A and the positions and types of variants with protein truncating variants shown below the protein (black and red lollipops) and missense variants and in-frame deletions (yellow and blue lollipops) shown above the protein. Whole gene deletions and the splice site variant are not shown on this figure. The three DNMT3A domains are shaded in grey: the proline-tryptophan-tryptophan-proline (PWWP) domain, the ATRX-Dnmt3-Dnmt3L (ADD) domain and the Methyltransferase (MTase) domain.](image-url)
<table>
<thead>
<tr>
<th>Case number</th>
<th>Nucleotide change</th>
<th>Protein change</th>
<th>Inheritance</th>
<th>BW/SD</th>
<th>BHC/SD</th>
<th>BL/SD</th>
<th>Age/yrs</th>
<th>Ht/SD</th>
<th>HC/SD</th>
<th>Wt/SD</th>
<th>ID</th>
<th>Behavioural issues</th>
<th>Joint hypermobility</th>
<th>Hypotonia</th>
<th>Kyphoscoliosis</th>
<th>Afebrile seizures</th>
<th>Other clinical issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>COG1849/217</td>
<td>c.26_27delinsT</td>
<td>de novo</td>
<td>10.0</td>
<td>nk</td>
<td>nk</td>
<td>nk</td>
<td>1.0</td>
<td>nk</td>
<td>nk</td>
<td>nk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG1919/1047</td>
<td>c.541C&gt;T</td>
<td>p.(Arg181Cys)</td>
<td>de novo</td>
<td>nk</td>
<td>nk</td>
<td>nk</td>
<td>11.3</td>
<td>3.1</td>
<td>1.6</td>
<td>2.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG2017/1145</td>
<td>c.759dupC</td>
<td>de novo</td>
<td>-0.4</td>
<td>nk</td>
<td>nk</td>
<td>nk</td>
<td>7.7</td>
<td>3.9</td>
<td>2.2</td>
<td>3.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG2019/2604</td>
<td>c.929T&gt;A</td>
<td>p.(Ile310Asn)</td>
<td>de novo</td>
<td>2.2</td>
<td>2.8</td>
<td>2.7</td>
<td>10.3</td>
<td>3.8</td>
<td>3.3</td>
<td>3.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG1962/2715</td>
<td>c.941G&gt;A</td>
<td>p.(Trp314Arg)</td>
<td>de novo</td>
<td>0.7</td>
<td>nk</td>
<td>nk</td>
<td>5.0</td>
<td>2.1</td>
<td>2.1</td>
<td>0.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG1998/2944</td>
<td>c.1154C&gt;T</td>
<td>p.(Pro385Leu)</td>
<td>de novo</td>
<td>-0.7</td>
<td>2.3</td>
<td>1.4</td>
<td>5.2</td>
<td>3.1</td>
<td>2.1</td>
<td>3.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG1974/2957</td>
<td>c.1296C&gt;G</td>
<td>p.(Tyr432X)</td>
<td>de novo</td>
<td>2.9</td>
<td>4.4</td>
<td>3.6</td>
<td>21.0</td>
<td>3.9</td>
<td>0.6</td>
<td>0.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG2007/2947</td>
<td>c.1320G&gt;A</td>
<td>p.(Trp440X)</td>
<td>de novo</td>
<td>1.8</td>
<td>nk</td>
<td>nk</td>
<td>10.5</td>
<td>3.2</td>
<td>1.3</td>
<td>1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG1925/1145</td>
<td>c.1523T&gt;C</td>
<td>p.(Leu508Pro)</td>
<td>de novo</td>
<td>2.8</td>
<td>6.5</td>
<td>3.8</td>
<td>6.3</td>
<td>4.0</td>
<td>3.6</td>
<td>3.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG0141/2715</td>
<td>c.1594G&gt;A</td>
<td>p.(Gly532Ser)</td>
<td>de novo</td>
<td>2.2</td>
<td>nk</td>
<td>nk</td>
<td>25.0</td>
<td>2.3</td>
<td>2.9</td>
<td>4.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG1995/2944</td>
<td>c.1594G&gt;A</td>
<td>p.(Gly532Ser)</td>
<td>de novo</td>
<td>3.9</td>
<td>nk</td>
<td>nk</td>
<td>22.0</td>
<td>2.9</td>
<td>3.6</td>
<td>3.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COG0422/2944</td>
<td>c.1643T&gt;A</td>
<td>p.(Met548Lys)</td>
<td>de novo</td>
<td>1.3</td>
<td>1.6</td>
<td>nk</td>
<td>15.3</td>
<td>1.4</td>
<td>3.4/12.8</td>
<td>3.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case number</td>
<td>Variant type</td>
<td>Nucleotide change</td>
<td>Protein change</td>
<td>Inheritance</td>
<td>BW/SD</td>
<td>BHC/SD</td>
<td>BL/SD</td>
<td>Age yrs</td>
<td>HV/SD</td>
<td>HC/SD</td>
<td>WV/SD</td>
<td>ID</td>
<td>Behavioural issues</td>
<td>Joint hypermobility</td>
<td>Hypotonia</td>
<td>Kyphoscoliosis</td>
<td>Amebic seizures</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------</td>
<td>-------------------</td>
<td>----------------</td>
<td>-------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>---------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>----</td>
<td>-------------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>COG2003/ DDD283776</td>
<td>missense</td>
<td>c.1643T&gt;C</td>
<td>p.(Met548Thr)</td>
<td>de novo</td>
<td>1.7</td>
<td>nk</td>
<td>nk</td>
<td>15.3</td>
<td>1.7</td>
<td>3.4</td>
<td>1.9</td>
<td>sev</td>
<td>AID</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG21288</td>
<td>missense</td>
<td>c.1645T&gt;C</td>
<td>p.(Cys548Arg)</td>
<td>de novo</td>
<td>1.1</td>
<td>1.6</td>
<td>2.6</td>
<td>17.9</td>
<td>16</td>
<td>3.6</td>
<td>2.6</td>
<td>mod</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>COG2010/ DDD283406</td>
<td>missense</td>
<td>c.1644T&gt;C</td>
<td>p.(Cys548Arg)</td>
<td>de novo</td>
<td>nk</td>
<td>nk</td>
<td>nk</td>
<td>9.5</td>
<td>17</td>
<td>0.35</td>
<td>1.05</td>
<td>yrs</td>
<td>mod</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG2003</td>
<td>missense</td>
<td>c.1743G&gt;C</td>
<td>p.(Trp581Cys)</td>
<td>de novo</td>
<td>-1.0</td>
<td>nk</td>
<td>nk</td>
<td>20.3</td>
<td>1.1</td>
<td>1.1</td>
<td>1.2</td>
<td>sev</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>COG2103/ DDD283343</td>
<td>missense</td>
<td>c.1743G&gt;T</td>
<td>p.(Trp581Cys)</td>
<td>de novo</td>
<td>0.7</td>
<td>nk</td>
<td>2.3</td>
<td>2.5</td>
<td>2.5</td>
<td>2.7</td>
<td>1.4</td>
<td>mod</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>COG2002</td>
<td>missense</td>
<td>c.1748G&gt;A</td>
<td>p.(Cys583Tyr)</td>
<td>de novo</td>
<td>2.5</td>
<td>nk</td>
<td>11</td>
<td>15.4</td>
<td>17</td>
<td>1.6</td>
<td>1.2</td>
<td>sev</td>
<td>regression</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>COG0510</td>
<td>stop gain</td>
<td>c.1803G&gt;a</td>
<td>p.(Trp601X)</td>
<td>de novo</td>
<td>2.9</td>
<td>nk</td>
<td>1.5</td>
<td>18.8</td>
<td>2.1</td>
<td>0.6</td>
<td>4.1</td>
<td>sev</td>
<td>obsessive</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG1972</td>
<td>splicing site</td>
<td>c.1861+3G&gt;C</td>
<td></td>
<td>de novo</td>
<td>1.3</td>
<td>nk</td>
<td>1.7</td>
<td>6.6</td>
<td>4.0</td>
<td>-1.2</td>
<td>3.1</td>
<td>mod</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>COG0553</td>
<td>missense</td>
<td>c.1943C&gt;T</td>
<td>p.(Lau648Pro)</td>
<td>de novo</td>
<td>-0.4</td>
<td>nk</td>
<td>nk</td>
<td>19.0</td>
<td>-2.5</td>
<td>3.1</td>
<td>4.3</td>
<td>mild</td>
<td>AID</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG0201</td>
<td>frameshift</td>
<td>c.2069delG</td>
<td></td>
<td>de novo</td>
<td>0.8</td>
<td>1.8</td>
<td>0.8</td>
<td>10.0</td>
<td>0.6</td>
<td>2.0</td>
<td>0.7</td>
<td>mild</td>
<td>no</td>
<td>nk</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG1942</td>
<td>missense</td>
<td>c.2046G&gt;C</td>
<td>p.(Trp682Cys)</td>
<td>de novo</td>
<td>0.4</td>
<td>nk</td>
<td>nk</td>
<td>21.0</td>
<td>3.7</td>
<td>2.5</td>
<td>1.4</td>
<td>18.9</td>
<td>yrs</td>
<td>mod</td>
<td>AID, severe psychosis and bipolar disorder</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>COG1888</td>
<td>missense</td>
<td>c.2099C&gt;T</td>
<td>p.(Pro700Leu)</td>
<td>de novo</td>
<td>1.2</td>
<td>nk</td>
<td>0.4</td>
<td>15.4</td>
<td>2.6</td>
<td>3.3</td>
<td>mod</td>
<td>AID</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>No</td>
</tr>
<tr>
<td>COG0316</td>
<td>missense</td>
<td>c.2141C&gt;G</td>
<td>p.(Ser714Cys)</td>
<td>de novo</td>
<td>1.2</td>
<td>nk</td>
<td>nk</td>
<td>4.4</td>
<td>3.0</td>
<td>1.4</td>
<td>2.9</td>
<td>sev</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>COG2004</td>
<td>missense</td>
<td>c.2204A&gt;C</td>
<td>p.(Ile734Ser)</td>
<td>de novo</td>
<td>1.6</td>
<td>nk</td>
<td>nk</td>
<td>20.0</td>
<td>2.5</td>
<td>2.8</td>
<td>2.5</td>
<td>mild</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG0447</td>
<td>missense</td>
<td>c.2207G&gt;a</td>
<td>p.(Arg736His)</td>
<td>de novo</td>
<td>1.0</td>
<td>nk</td>
<td>0.6</td>
<td>8.5</td>
<td>3.0</td>
<td>2.0</td>
<td>2.5</td>
<td>mild</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG1895</td>
<td>missense</td>
<td>c.2345C&gt;T</td>
<td>p.(Arg782Cys)</td>
<td>de novo</td>
<td>0.8</td>
<td>0.6</td>
<td>2.0</td>
<td>15.5</td>
<td>2.8</td>
<td>3.8</td>
<td>3.8</td>
<td>mod</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>COG2005</td>
<td>missense</td>
<td>c.2346C&gt;T</td>
<td>p.(Arg782Cys)</td>
<td>de novo</td>
<td>-1.0</td>
<td>nk</td>
<td>0.4</td>
<td>23.0</td>
<td>0.5</td>
<td>2.7</td>
<td>mod</td>
<td>AID, psychosynthesis and schizophrenia</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>No</td>
</tr>
<tr>
<td>COG0538</td>
<td>missense</td>
<td>c.2346T&gt;G</td>
<td>p.(Arg782Gln)</td>
<td>de novo</td>
<td>0.3</td>
<td>nk</td>
<td>nk</td>
<td>20.8</td>
<td>1.2</td>
<td>1.3</td>
<td>4.4</td>
<td>mod</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG1635/ DDD283319</td>
<td>in-frame deletion</td>
<td>c.2355_2357delCT</td>
<td></td>
<td>de novo</td>
<td>1.8</td>
<td>2.2</td>
<td>2.5</td>
<td>nk</td>
<td>nk</td>
<td>nk</td>
<td>mod</td>
<td>no</td>
<td>nk</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>No</td>
</tr>
<tr>
<td>COG15112</td>
<td>frameshift</td>
<td>c.2297delA</td>
<td></td>
<td>de novo</td>
<td>4.0</td>
<td>3.5</td>
<td>nk</td>
<td>13.3</td>
<td>3.8</td>
<td>1.5</td>
<td>1.9</td>
<td>mod</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG2011</td>
<td>missense</td>
<td>c.2309C&gt;T</td>
<td>p.(Ser770Leu)</td>
<td>de novo</td>
<td>0.9</td>
<td>nk</td>
<td>nk</td>
<td>16.3</td>
<td>2.6</td>
<td>-0.1</td>
<td>0.4</td>
<td>mod</td>
<td>Bipolar disorder</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Case number</td>
<td>Variant type</td>
<td>Nucleotide change</td>
<td>Protein change</td>
<td>Inheritance</td>
<td>BW/SD</td>
<td>BHC/SD</td>
<td>BL/SD</td>
<td>Age yrs</td>
<td>Ht/SD</td>
<td>HC/SD</td>
<td>Wt/SD</td>
<td>ID</td>
<td>Behavioural issues</td>
<td>Joint hypermobility</td>
<td>Hypotonia</td>
<td>Kyphoscoliosis</td>
<td>Intellectual disability</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------</td>
<td>------------------</td>
<td>----------------</td>
<td>-------------</td>
<td>-------</td>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>----</td>
<td>-------------------</td>
<td>-------------------</td>
<td>----------</td>
<td>------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>COG1971</td>
<td>missense</td>
<td>c.2312G&gt;A</td>
<td>p.(Arg771Gln)</td>
<td>de novo</td>
<td>1.2</td>
<td>nk</td>
<td>nk</td>
<td>3.1</td>
<td>3.4</td>
<td>3.4</td>
<td>3.1</td>
<td></td>
<td>mod</td>
<td>ASD</td>
<td>nk</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>COG1964</td>
<td>missense</td>
<td>c.2671A&gt;G</td>
<td>p.(Met891Val)</td>
<td>de novo</td>
<td>3.0</td>
<td>2.8</td>
<td>2.6</td>
<td>8.8</td>
<td>2.1</td>
<td>0.2</td>
<td>2.0</td>
<td></td>
<td>mod</td>
<td>regression</td>
<td>yes</td>
<td>nk</td>
<td>yes</td>
</tr>
<tr>
<td>COG1771</td>
<td>missense</td>
<td>c.2661G&gt;T</td>
<td>p.(Arg882Cys)</td>
<td>de novo</td>
<td>0.6</td>
<td>0.5</td>
<td>0.6</td>
<td>2.0</td>
<td>2.7</td>
<td>0.3</td>
<td>2.0</td>
<td></td>
<td>mod</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>COG1945</td>
<td>stop gain</td>
<td>c.2661G&gt;T</td>
<td>p.(Ser892X)</td>
<td>de novo</td>
<td>0.7</td>
<td>nk</td>
<td>1.5</td>
<td>9.5</td>
<td>12.9</td>
<td>4.2</td>
<td>3.0</td>
<td></td>
<td>mod</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG2012</td>
<td>missense</td>
<td>c.2661G&gt;T</td>
<td>p.(Ser892X)</td>
<td>de novo</td>
<td>0.8</td>
<td>nk</td>
<td>1.5</td>
<td>9.5</td>
<td>12.9</td>
<td>4.2</td>
<td>3.0</td>
<td></td>
<td>mod</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>COG1813</td>
<td>gene del</td>
<td>c.2661G&gt;T</td>
<td>p.(Phe904Leu)</td>
<td>de novo</td>
<td>1.2</td>
<td>nk</td>
<td>0.0</td>
<td>9.5</td>
<td>13.0</td>
<td>4.2</td>
<td>3.0</td>
<td></td>
<td>mod</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>COG2014</td>
<td>gene del</td>
<td>c.2661G&gt;T</td>
<td>p.(Phe904Leu)</td>
<td>de novo</td>
<td>0.8</td>
<td>0.6</td>
<td>0.2</td>
<td>2.0</td>
<td>2.7</td>
<td>0.3</td>
<td>2.0</td>
<td></td>
<td>mod</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>no</td>
</tr>
</tbody>
</table>

Abbreviations: nk, not known; ID, intellectual disability; CAL, café au lait; SD, standard deviation; gene del, whole gene deletion; BW, birth weight; BHC, birth head circumference; BL, birth length; Ht, height; Wt, weight; HC, head circumference; mod, moderate; sev, severe; ASD, autistic spectrum disorder; br MRI, brain magnetic resonance imaging; AML, acute myeloid leukaemia; FAB, Franco-American-British; ADHD, attention deficit hyperactivity disorder; AVNRT, atrio-ventricular nodal re-entry tachycardia
age-related clonal haematopoiesis, limiting the utility of databases such as gnomAD in DNMT3A variant pathogenicity stratification (Supplementary Table 1)

Results
All 55 individuals had an intellectual disability: 18% had a mild intellectual disability (10/55); 65% had a moderate intellectual disability (36/55) and 16% had a severe intellectual disability (9/55) (Table 1, Figure 2). Behavioural/psychiatric issues were reported in 51% (28/55) individuals and included combinations of autistic spectrum disorder (20 individuals); anxiety (three individuals); neurodevelopmental regression (four individuals two of whom regressed in teenage years); psychosis/schizophrenia (three individuals); aggressive outbursts (two individuals), and bipolar disorder (two individuals) (Table 1).

Postnatal overgrowth (defined as height and/or head circumference at least two standard deviations above the mean (≥2SD)) was reported in 83% (44/53) individuals. Obesity, with a weight ≥2SD, was reported in 67% (34/51). The range of individual postnatal heights, head circumferences and weights is shown in Table 1 and Figure 3. The mean birth weight was 1.3SD with a range from -1.1 to 4.0 SD. We had limited data for birth head circumference and birth length, but their mean was 2.3SD and 1.6SD, respectively.

There were some shared, but subtle, facial characteristics often only becoming apparent in early adolescence (Figure 4a and b). These included low-set, horizontal thick eyebrows; narrow palpebral fissures; coarse features and a round face. The two upper central incisors were also frequently enlarged and prominent.

Additional clinical features reported in greater than 20% (≥11) individuals included: joint hypermobility (74%, 37/50); hypotonia (54%, 28/52); kyphoscoliosis (33%, 18/55) and afebrile seizures (22%, 12/55) (Table 1). In addition, short, widely spaced toes were frequently mentioned, but the overall frequency is unclear as we did not specifically ask about feet/toes on the clinical proforma (Figure 4c).

Clinical features reported in at least two but fewer than 20% individuals included cryptorchidism (six individuals); ventriculomegaly (four individuals) and Chiari malformation (three individuals). In addition, a range of cardiac anomalies (including atrial septal defect, mitral/tricuspid valve incompetence, patent ductus arteriosus, aortic root enlargement and atrio-ventricular re-entry tachycardia) were reported in nine individuals. However, of note, two individuals with cardiac anomalies (patent ductus arteriosus, COG1961 and COG2006) were identical twins with DNMT3A whole gene deletions encompassing ≥40 genes. The patent ductus arteriosus in these individuals may, therefore, be attributable to twinning, alternative genes in the deleted region or the combined effect of a number of deleted genes.

Acute myeloid leukaemia (AML), AML-FAB (French-American-British classification) type M4, was diagnosed in one individual at the age of 12 years (COG2004). This individual had a de novo heterozygous c.2204A>C p.(Tyr735Ser) DNMT3A variant, identified in DNA obtained seven years prior to the diagnosis of AML.

Full clinical details from the 55 individuals are provided in Table 1.

Discussion
We have evaluated clinical data from 55 individuals with de novo constitutive DNMT3A variants to define the phenotype of TBRS. An intellectual disability (most frequently in the moderate range) and overgrowth (defined as height and/or head circumference ≥2SD above the mean) were reported in ≥80% of individuals and have been designated major clinical associations. Frequent clinical associations, reported in 20–80% of individuals with constitutive DNMT3A variants, included joint hypermobility, obesity, hypotonia, behavioural/psychiatric issues (most frequently autistic spectrum disorder), kyphoscoliosis and afebrile seizures. In addition, many individuals had a characteristic facial appearance although this may only be recognizable in adolescence.

TBRS overlaps clinically with other OGIS syndromes including Sotos syndrome (OMIM 117550), Weaver syndrome (OMIM 277590), Malan syndrome (OMIM 614753) and the OGIS syndrome due to CHD8 gene variants. However, TBRS is more frequently associated with increased weight than the other OGIS syndromes and may be distinguishable through recognition of the associated facial features, and absence of the facial gestalt of other OGIS syndromes.

Somatic DNMT3A variants are known to drive the development of adult AML and myelodysplastic syndrome and over half of the DNMT3A somatic variants target a single residue, the p.Arg882 residue. AML, diagnosed in childhood, has now been identified in two individuals with (likely) constitutive DNMT3A variants from a total of 77 (1/55 individuals in the current study and 1/22 previously reported individuals). One of these individuals had a
Figure 3. Growth profile in individuals with TBRS a) height, b) head circumference and c) weight. The blue line represents the mean.
Figure 4. a) The facial appearance of children and adults with TBRS; b) the evolving facial appearance in four individuals with TBRS; and c) the characteristic short, widely spaced toes seen in TBRS.
de novo c.2644CT p.(Arg882Cys) DNMT3A variant and developed AML at 15 years of age. The variant was present in genomic DNA extracted from the patient’s remission blood sample and skin fibroblasts. The second individual had a c.2204A>C p.(Tyr735Ser) DNMT3A variant identified in DNA obtained at 5 years of age and developed AML at the age of 12 years. Whilst these data indicate that AML may be a rare association of TBRS, currently the numbers of individuals reported with TBRS and AML are too few to either accurately quantify the risk of AML in TBRS or determine whether this risk is influenced by the underlying DNMT3A genotype. Further studies are required to address this.

The majority of individuals with TBRS are healthy and do not require intensive clinical follow up. However, our practice is to inform families and paediatricians of the possible TBRS complications of behavioural/psychiatric issues, kyphoscoliosis and afebrile seizures to introduce a low threshold for their investigation and/or management. In addition, we undertake a baseline echocardiogram at initial diagnosis to investigate cardiac anomalies detectable on ultrasound scan and frequently refer patients to physiotherapy to evaluate the degree of hypotonia and/or joint hypermobility and to determine whether targeted exercises may be beneficial. Finally, in the absence of evidence-based surveillance protocols for haematological malignancies, we advise clinical vigilance for symptoms possibly related to a haematological malignancy such as easy bruising, recurrent bleeding from gums or nosebleeds, persistent tiredness and recurrent infections.

Ethics and consent
The study was approved by the London Multicentre Research Ethics Committee (MREC MREC/01/2/44).

Written informed consent was obtained from participants and/or parents for participation in the study (n=55) and publication of photographs of participants shown in Figure 4 (n=41).

Data availability
All data underlying the results are available as part of the article and no additional source data are required.

Competing interests
No competing interests were disclosed.

Grant information
K.T.-B. is supported by funding from the Child Growth Foundation (GR01/13) and the Childhood Overgrowth Study is funded by the Wellcome Trust [100210].

The CAUSES Study is funded by Mining for Miracles, British Columbia Children’s Hospital Foundation and Genome British Columbia.

The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute [098051]. The DDD study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC).

The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. This study makes use of DECIPHER (http://decipher.sanger.ac.uk), which is funded by the Wellcome Trust.

The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the Department of Health.

Acknowledgements
We thank the patients and families for their active participation in this study and the clinicians that recruited them. The full list of collaborators is in Supplementary File 1. We also acknowledge the contribution Amanda Springer who helped in the recruitment of patient COG1945 and of the CAUSES Study whose investigators include: Shelin Adam, Christele Du Souich, Jane Gillis, Alison Elliott, Anna Lehman, Jill Mwenifumbo, Tanya Nelson, Clara Van Karnebeek, Sylvia Stockler, James O’Byrne and Jan Friedman. All are affiliated with the University of British Columbia, Vancouver, Canada. In addition, we would like to thank the DDD study for their collaboration.


Open Peer Review

Current Peer Review Status: ✔️ ✔️ ✔️

Version 1

Reviewer Report 29 May 2018

https://doi.org/10.21956/wellcomeopenres.15708.r33053

© 2018 Shen W. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Wei Shen
ARUP Laboratories, Salt Lake City, UT, USA

In this very well written manuscript, the authors described the largest cohort of patients with the Tatton-Brown-Rahman syndrome (TBRS) to date, and further delineated the clinical phenotype associated with TBRS. It would be very interesting to explore any genotype-phenotype correlations in this cohort combined with other patients reported in the literature if needed. For example, the individuals without overgrowth in this cohort all had missense variants, whereas all patients with clearly loss-of-function variants including truncating (nonsense and frame-shift) variants or gene-deletions exhibited overgrowth. While the functional consequences of Arg882 missense variants (p.Arg882His and p.Arg882Cys) were investigated in both somatic and germline settings (Spencer DH et al. Cell 2017, Russler-Germain et al. Cancer Cell 2014), the effects of other missense variants on DNMT3A function are still unclear (presumably loss-of-function). It would be also interesting to see how many of the DNMT3A germline variants reported here were also observed as somatic mutations in leukemia.

Minor points:
1. Please describe the protein changes for the indel variants in Table 1 according to syntax recommended by HGVS.
2. Please change “c.2644CT” to “c.2644C>T” in the top line on page 11.
3. Was any patient (other than the 13 patients first reported in the 2014 Nat Genet paper) previously reported? If so, please reference the original publication.

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

——

Review Report 18 May 2018

https://doi.org/10.21956/wellcomeopenres.15708.r33035

© 2018 Gibson W et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

William T. Gibson
Diabetes Research Group, BC Children's Hospital Research Institute, Vancouver, BC, Canada

Sharri Cyrus
Diabetes Research Group, BC Children's Hospital Research Institute, Vancouver, BC, Canada

This is a very well written article, which expands on the previously-reported phenotype and recommends management guidelines for a rare and recently-described syndrome. The inclusion of multiple patient photos and clinical details will be quite helpful for other physicians who have one or more patients with rare variants in this gene. Similarly, the aggregation of the rare variants with clinical annotations will assist clinical diagnostic labs in the interpretation of rare variants they encounter in NGS panels, clinical exomes and whole genomes.

The authors mention “joint hypermobility” as a feature, but do not offer additional details. In clinical practice, one frequently encounters patients who claim to have joint hypermobility (or to have had it in the past), yet the degree of hypermobility and the number of joints affected varies greatly from patient to patient. Thus, the phenotypic spectrum of “joint hypermobility” can vary, from minor painless hyperextensibility of the small joints of the hands in childhood all the way to significantly increased range of motion among both large and small joints that persists into adulthood. A full assessment of the Beighton scale and of range-of-motion of the other joints is not likely to have been documented by all referring clinicians, but perhaps the column on “Joint hypermobility” could be split into two columns such as “Joint hypermobility – history” (for patients who report it as a symptom) and “Joint hypermobility – demonstrated” (for patients in whom hypermobility is documented as a sign on physical exam). Alternatively, the categories “nk” “no” and “yes” could be adjusted to “nk” “no” “yes (hist)” and “yes (exam)” or something similar.

Many of the facial photos presented appear to show downslanted palpebral fissures, yet the authors comment only on “narrow palpebral fissures” in the article. Do the authors have enough data to comment
on this feature, and/or could they have the available facial photographs evaluated systematically for this feature? It is likely to be some time before another cohort of this size or larger is assembled and published, so it may be worthwhile to investigate this aspect of the facial gestalt in a little more detail. It would also be helpful for the authors to comment on the presence or absence of hypertelorism, as some dysmorphologists consider an interpupillary distance greater than the 97th percentile for age to be a useful sign in the assessment of OGIS, whereas others “adjust” the eye spacing in light of the head circumference (which is frequently >+2SD for age in OGID).

Minor Spelling and Grammatical Errors:

In the abstract, the authors state “weight 3SD” – perhaps they mean “weight >+2SD” or “weight Z-score +2 or higher”?

In the abstract, “TBRS” should be followed by a period.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: These two referees work in the same department as do the members of the CAUSES study. The CAUSES study contributed patients to this clinical cohort. This review was not discussed with the members of the CAUSES study prior to its submission.

Reviewer Expertise: OGIS, PRC2 Complex, Epigenetic risk factors for rare diseases, Intracranial Aneurysms

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 02 May 2018

https://doi.org/10.21956/wellcomeopenres.15708.r32979
Emma L. Wakeling
North West Thames Regional Genetics Service, London North West Healthcare NHS Trust, London, UK

This is a concise and well-written paper summarising the clinical phenotype in 55 patients with Tatton-Brown-Rahman syndrome due to de novo constitutive DNMT3A variants. The findings are clearly presented with the use of figures and detailed clinical information in table 1.

Minor comments are as follows:
1. The abstract list of frequent associations should be slightly re-punctuated for clarity: ‘behavioural/psychiatric issues, most frequently autistic spectrum disorder (51%);’
2. There is no indication of the male: female ratio within the cohort. This is relevant to the frequency of cryptorchidism in affected males.
3. Although increased weight (≥2 SD) is clearly a feature (Figure 3), this is in the context of overgrowth (height and/or head circumference ≥2 SD). It would be helpful to know the frequency of true obesity (BMI ≥ 30) and to make this distinction in the paper.
4. Although the focus of the paper is a clinical description of TBRS, it would be helpful to discuss briefly the clustering of missense and in-frame deletions (with two exceptions) within the three DNMT3A domains and possible genotype-phenotype correlation (this is only mentioned in the context of AML).

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.